Bajaj Healthcare Q4 FY26 Preview: 9% Sales Growth

What investors are tracking ahead of Q4 FY26

Bajaj Healthcare Ltd. is yet to announce the date for its Q4 FY26 results, as per a preview note dated March 13, 2026. Market attention is on whether the company can extend the momentum seen in Q3 FY26, when revenue and profits improved year-on-year. The same preview note points to expectations of higher sales and a meaningful rise in profit after tax (PAT).

The company’s last reported earnings update was for Q3 FY26, with an earnings date stated as January 16, 2026. For that quarter, multiple data points in the provided information indicate revenue of about ₹161 crore and net profit of about ₹15 crore. Separately, the standalone financial table provides figures in ₹ lakh, which convert to similar ₹ crore numbers.

Q4 FY26 expectations: revenue, PAT, and EBITDA

The March 13, 2026 preview indicates analysts are pencilling in around 9% year-on-year revenue growth for Q4 FY26. PAT is projected to rise 18% year-on-year, while EBITDA is expected to increase by 5%. The note attributes expectations to higher sales, order execution, margin improvement, and a strong order book.

Importantly, these are expectations and not company guidance in the provided text. The actual Q4 performance will depend on execution and operating conditions during the quarter. The results date itself is described as “all set to be announced soon,” indicating investors may need to wait for an exchange filing or official communication.

Q3 FY26 snapshot: growth on both YoY and QoQ basis

For Q3 FY26 (quarter ended December 31, 2025), the dataset highlights revenue of ₹161 crore, up 31.30% year-on-year and 9.00% quarter-on-quarter. Gross profit is listed as ₹23 crore, up 58.86% year-on-year and 18.23% quarter-on-quarter. Net profit is shown as ₹15 crore, up 33.70% year-on-year and 41.17% quarter-on-quarter.

The standalone financial table (₹ lakh) aligns with the same direction of change. Revenue from operations is reported at ₹16,122.27 lakh (₹161.22 crore) versus ₹12,279.40 lakh (₹122.79 crore) in Q3 FY25. Profit for the period is reported at ₹1,567.38 lakh (₹15.67 crore) in Q3 FY26.

EBITDA and margins: operating leverage visible in Q3

The provided summary also states EBITDA for Q3 FY26 at ₹30.70 crore versus ₹21.60 crore in Q3 FY25, a rise of 42.13%. EBITDA margin is listed at 19.03% compared with 17.62% a year earlier, an improvement of 141 basis points.

Alongside top-line growth, the company’s total income for the quarter is shown at ₹16,286.98 lakh (₹162.87 crore) in the standalone table. Total expenses are reported at ₹14,362.52 lakh (₹143.63 crore). The combination of higher income and controlled cost structure relative to revenue is consistent with the margin expansion described.

Nine-month performance: revenue crosses ₹450 crore

For the nine-month period ended December 31, 2025, revenue from operations is shown at ₹45,797.39 lakh (₹457.97 crore), up from ₹38,812.99 lakh (₹388.13 crore) in the corresponding period of FY25. Net profit for nine months is listed as ₹3,861.67 lakh (₹38.62 crore), up from ₹2,831.77 lakh (₹28.32 crore).

The same dataset also includes nine-month total income of ₹46,215.16 lakh (₹462.15 crore) and total expenses of ₹41,241.98 lakh (₹412.42 crore). These figures provide context on scale and profitability trends as investors look to Q4.

Auditor review: unmodified conclusion under limited review

The auditor’s review report by Walker Chandiok & Co LLP is described as clean, with no qualifications, concerns, or issues. The review is stated to be conducted under SRE 2410 and is limited in scope compared to a full audit. The financial results are said to be prepared under Ind AS 34.

This matters mainly because it reduces uncertainty around the quarterly numbers, especially when market narratives are focused on strong growth and profitability. The provided information also clarifies that only standalone financial results are included and consolidated results are not provided.

Discontinued operations and other corporate actions

The standalone filing includes a discontinued operations section, where total income and expenses are reported separately. Another summary line states that discontinued operations incurred losses but were reducing compared to prior periods, and also flags higher deferred tax charge in Q3 FY26 compared with Q3 FY25.

On corporate actions, the company is stated to have declared a dividend of ₹1.00 on September 19, 2025. The last bonus issue is stated as February 19, 2019. The reported EPS is mentioned as 14.79 (with estimated EPS shown as “--”), while the Q3 FY26 basic EPS from total operations is also stated as ₹4.96.

Stock price references cited in the provided data

Two separate price references appear in the text. One line states Bajaj Healthcare shares closed at ₹389.30 on January 16, 2026, down ₹4.85 or 1.23% on the day. The March 13, 2026 preview note states the share price was trading at ₹291 per share on that date, and adds that the stock was up 18% over six months and up 51% over one year, with a 231% return over five years.

These are point-in-time snapshots from the provided sources and should be read with their respective dates.

Key numbers table (standalone)

Why this preview matters for Q4 positioning

Q3 FY26 showed a combination of strong year-on-year revenue growth and faster growth in EBITDA and net profit, based on the figures provided. That sets a higher base for Q4 comparisons, which is why even a 9% year-on-year revenue growth expectation is being highlighted in the preview note. The clean limited review opinion also provides comfort that reported standalone numbers align with the review procedures described.

For investors, the key near-term trigger is the official announcement of the Q4 FY26 results date, followed by clarity on whether revenue momentum and operating margins hold. Based on the provided information, the next concrete update is expected when the company announces its Q4 FY26 results schedule.